<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
x

Activating Mutations in MYD88 and CD79B Are Predictive of Response to Ibrutinib in ABC-DLBCL Tumors

DLBCL is the most common form of nonHodgkin’s lymphoma (NHL) consisting in 2 subtypes: the activated B cell-like (ABC) and the germinal center B cell-like (GCB).